Applied BioCode Osake

Applied BioCode Bruttotulos

Bruttotulos yhtiöstä Applied BioCode (6598.TW) 1.8.2026 päivämäärällä on 260,89 M TWD. Edellisenä vuonna Bruttotulos oli 204,00 M TWD — muutos 27,89 % (korkeampi).

Bruttotulos

260,89 MTWD

YoY

27,89%

Viimeksi päivitetty:

Bruttotulos yhtiöstä Applied BioCode on 2026 260,89 M TWD. Bruttotulos yhtiöstä Applied BioCode oli 2025 204,00 M TWD. Se laskee 27,89% korkeampi edelliseen vuoteen verrattuna.

Applied BioCode Bruttotulos historia

  • 3 vuotta

  • 10 vuotta

  • 25 vuotta

  • Maksimi

BRUTTOKATE (%)
Date
BRUTTOKATE (%)
1.1.2019
5 059,00 base
1.1.2020
6 472,00 base
1.1.2021
5 918,00 base
1.1.2022
6 000,00 base
1.1.2023
6 801,00 base
1.1.2024
5 946,00 base
1.1.2025
5 490,00 base
1.1.2026 (e)
0,00 base
VUOSIBRUTTOKATE (%)
2026 est -
2025 54,90
2024 59,46
2023 68,01
2022 60,00
2021 59,18
2020 64,72
2019 50,59
2018 45,05
2017 33,32
2016 41,62
2015 26,84
2014 17,95
2013 7,58
Access this data via the Eulerpool API

Applied BioCode Liikevaihto

Applied BioCode osakkeen liikevaihto, EBIT, voitto

  • 3 vuotta

  • 5 vuotta

  • 10 vuotta

  • 25 vuotta

  • Maksimi

Liikevaihto
EBIT
Voitto
Details
Date
Liikevaihto
EBIT
Voitto
1.1.2019
104,69 M TWD
−273,46 M TWD
−280,07 M TWD
1.1.2020
299,02 M TWD
−99,16 M TWD
−103,50 M TWD
1.1.2021
319,96 M TWD
−162,31 M TWD
−165,20 M TWD
1.1.2022
390,30 M TWD
−181,93 M TWD
−184,73 M TWD
1.1.2023
395,17 M TWD
−186,70 M TWD
−164,20 M TWD
1.1.2024
343,07 M TWD
−277,67 M TWD
−260,81 M TWD
1.1.2025
475,20 M TWD
−223,33 M TWD
−201,20 M TWD
1.1.2026 (e)
0,00 TWD
0,00 TWD
0,00 TWD

Applied BioCode Katteprosentit

Applied BioCode osakkeen marginaalit

Applied BioCode Margenanalyysi näyttää bruttomarginaalin, EBIT-marginaalin sekä voittomarginaalin Applied BioCode osalta. EBIT-marginaali (EBIT/liikevaihto) kertoo, kuinka suuri osuus liikevaihdosta jää operatiivisena voittona. Voittomarginaali näyttää, kuinka suuri osuus Applied BioCode liikevaihdosta säilyy.
  • 3 vuotta

  • 5 vuotta

  • 10 vuotta

  • 25 vuotta

  • Maksimi

Bruttokate
EBIT-marginaali
Voittomarginaali
Details
Date
Bruttokate
EBIT-marginaali
Voittomarginaali
1.1.2019
50,59 %
−261,20 %
−267,52 %
1.1.2020
64,72 %
−33,16 %
−34,61 %
1.1.2021
59,18 %
−50,73 %
−51,63 %
1.1.2022
60,00 %
−46,61 %
−47,33 %
1.1.2023
68,01 %
−47,25 %
−41,55 %
1.1.2024
59,46 %
−80,94 %
−76,02 %
1.1.2025
54,90 %
−47,00 %
−42,34 %
1.1.2026 (e)
54,90 %
0,00 %
0,00 %

Applied BioCode Osakeanalyysi

Mitä Applied BioCode tekee? Applied BioCode Corp is a California-based company that focuses on the development and marketing of diagnostic instruments and tests. The company was founded in 2004 by an experienced management team and has since developed a number of groundbreaking technologies to improve the diagnosis of diseases such as cancer, infectious diseases, and autoimmune diseases. The business model of Applied BioCode Corp is based on the development of innovative diagnostic instruments and test systems based on proprietary technologies. The company has a strong partnership with a leading manufacturer of diagnostic automation systems, allowing a wide range of tests for various diseases to be offered. Applied BioCode Corp also works closely with leading research and development organizations to leverage the latest insights in the field of diagnostics. One of the divisions of Applied BioCode is molecular diagnostics, which is an essential component of modern medicine. Molecular diagnostics enables the detection of genetic changes and deviations related to diseases. Applied BioCode's technology allows for rapid and precise identification of pathogens in clinical samples such as blood, urine, and tissue samples. Another important area for Applied BioCode is infectious disease diagnostics. The company has developed a range of test systems based on a variety of infectious diseases such as influenza, tuberculosis, and sexually transmitted diseases such as chlamydia and gonorrhea. These tests can be performed individually or as a group to facilitate disease diagnosis and improve treatment. Applied BioCode also offers tests for the detection of oncological markers. These tests are crucial for the early detection of cancer and monitoring the treatment of cancer patients. Applied BioCode's technology enables rapid and precise identification of cancer cells in blood or tissue, which can improve the effectiveness of treatment. Another important product of Applied BioCode is the BioCode Analyzer, an automated diagnostic instrument. The BioCode Analyzer is a high-throughput system capable of performing multiple tests simultaneously. The analyzer is equipped with a disposable chip that allows for quick and easy diagnosis. This makes the BioCode Analyzer a powerful tool for laboratory automation, providing fast and accurate diagnosis for a variety of diseases. Applied BioCode is also dedicated to researching and developing new technologies. The company has an active pipeline of new products and technologies to further improve diagnostic accuracy and the number of feasible tests. Applied BioCode is also developing new applications for its technologies to improve the diagnosis and treatment of diseases in various ways. In summary, Applied BioCode Corp plays an important role in the field of diagnostic technology. The company has developed a wide range of innovative diagnostic tests and instruments that enable diseases to be quickly and accurately detected. With its strong partnership with leading diagnostic automation system manufacturers and research organizations, Applied BioCode will continue to stay at the forefront and improve diagnostic practice. Applied BioCode on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Applied BioCode osakkeesta

Yhtiön Applied BioCode Bruttotulos on 260,89 M TWD vuonna 2026.

Access this data via the Eulerpool API

Tuloslaskelma — Applied BioCode

Kaikki tunnusluvut — Applied BioCode